Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Immanuel Medical Center
mi
from
Omaha, NE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Immanuel Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Alegent Health Cancer Center at Bergan Mercy Medical Center
mi
from
Omaha, NE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Alegent Health Cancer Center at Bergan Mercy Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Creighton University Medical Center
mi
from
Omaha, NE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Creighton University Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Mount Sinai Hospital
mi
from
New York, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Veterans Affairs Medical Center - Syracuse
mi
from
Syracuse, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Veterans Affairs Medical Center - Syracuse
mi
from
Syracuse, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Faxton Regional Cancer Center
mi
from
Utica, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Faxton Regional Cancer Center
mi
from
Utica, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Pardee Memorial Hospital
mi
from
Hendersonville, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Pardee Memorial Hospital
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Kinston Medical Specialists
mi
from
Kinston, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Kinston Medical Specialists
mi
from
Kinston, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Cancer Care Associates - Mercy Campus
mi
from
Oklahoma City, OK
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Cancer Care Associates - Mercy Campus
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Miriam Hospital
mi
from
Providence, RI
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Mountainview Medical
mi
from
Berlin, VT
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Mountainview Medical
mi
from
Berlin, VT
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Danville Regional Medical Center
mi
from
Danville, VA
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Danville Regional Medical Center
mi
from
Danville, VA
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Stanford University
mi
from
Stanford, CA
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Univ of Minnesota
mi
from
Minneapolis, MN
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Ohio State University
mi
from
Columbus, OH
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Vanderbilt University
mi
from
Nashville, TN
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Fred Hutchinson Cancer Research Center - Seattle Cancer Care Alliance
mi
from
Seattle, WA
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Fred Hutchinson Cancer Research Center - Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Mayo Clinic
mi
from
Scottsdale, AZ
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Washington University, St. Louis
mi
from
St. Louis, MO
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Washington University, St. Louis
mi
from
St. Louis, MO
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Weill-Cornell Medical College
mi
from
New York, NY
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm
Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm
Status: Enrolling
Updated:  11/24/2015
SUNY Upstate Medical University
mi
from
Syracuse, NY
Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm
Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm
Status: Enrolling
Updated: 11/24/2015
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Zinc and Diabetes in Patients With Thalassemia: a Pilot Study
Zinc and Diabetes in Patients With Thalassemia: a Pilot Study
Status: Enrolling
Updated:  11/25/2015
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Zinc and Diabetes in Patients With Thalassemia: a Pilot Study
Zinc and Diabetes in Patients With Thalassemia: a Pilot Study
Status: Enrolling
Updated: 11/25/2015
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
A Phase I Trial of Ruxolitinib Combined With Tacrolimus and Sirolimus as Acute Graft-versus-Host Disease (aGVHD) Prophylaxis During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Status: Enrolling
Updated:  11/25/2015
City of Hope Medical Center
mi
from
Duarte, CA
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
A Phase I Trial of Ruxolitinib Combined With Tacrolimus and Sirolimus as Acute Graft-versus-Host Disease (aGVHD) Prophylaxis During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Status: Enrolling
Updated: 11/25/2015
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
Phase II Trial of Low Dose Decitabine (Dacogen) in Patients With Primary Myelofibrosis and Post ET/PV Myelofibrosis
Status: Enrolling
Updated:  11/25/2015
The Mayo Clinic
mi
from
Rochester, MN
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
Phase II Trial of Low Dose Decitabine (Dacogen) in Patients With Primary Myelofibrosis and Post ET/PV Myelofibrosis
Status: Enrolling
Updated: 11/25/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Phoenix, AZ
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Orange, CA
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Orange, CA
Click here to add this to my saved trials
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tampa, FL
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Atlanta, GA
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Atlanta, GA
Click here to add this to my saved trials